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Background
The ubiquitously expressed soluble guanylyl cyclase
(sGC) converts guanosine 5'-triphosphate (GTP) to gua-
nosine 3':5'-cyclic monophosphate (cGMP). The het-
erodimeric protein is activated by nitric oxide (NO). sGC
plays a key role in the regulation of vascular tone and neu-
rotransmission. Hence, sGC is an important target for the
treatment of cardiovascular diseases e.g. pulmonary
hypertension, heart failure and coronary heart disease. In
addition to the biosynthesis of cGMP, we had previously
shown by radiochemical analysis that sGC also generates
the cyclic pyrimidine nucleotide uridine 3':5'-cyclic
monophosphate (cUMP)[1]. However, cUMP could only
be described as putative product but an exact identifica-
tion by structure analysis was still missing. Therefore, we
have established a new analytical method based on high
performance liquid chromatography/mass spectrometry
(HPLC-MS/MS) [see poster: CM Spangler et al.]. In com-
parison with classic radiochemical assays an analysis by
HPLC-MS/MS allows the detection of non-radioactive
compounds. Accordingly, a broader spectrum of sub-
strates that is not available for radioactive assays can be
used. Additionally, different nucleotides can be detected
at the same time and the detection is directly structure-
based. Making use of the new HPLC-MS/MS method we
systematically characterised the substrate specificity of
sGC.
Materials and methods
Highly purified recombinant sGC from rat (α1β1) was
activated by sodium nitroprusside (100 μM). sGC (5 ng/
tube) was incubated at 37°C with 3 mM MnCl2 and 200
μM of various nucleoside 5'-triphosphates (NTPs). Sam-
ples were stopped by heating at 95°C after 20 minutes.
Concentrations of adenosine 3':5'-cyclic monophosphate
(cAMP), inosine 3':5'-cyclic monophosphate (cIMP), uri-
dine 3':5'-cyclic monophosphate (cUMP), cytidine 3':5'-
cyclic monophosphate (cCMP) and thymidine 3':5'-cyclic
monophosphate (cTMP) were determined by HPLC-MS/
MS.
Results
We could demonstrate that besides GTP, sGC converts
adenosine 5'-triphosphate (ATP), inosine 5'-triphosphate
(ITP) and uridine 5'-triphosphate (UTP) to their corre-
sponding cyclic nucleoside 3':5'-cyclic monophosphates
(cNMPs). In relation to cGMP-synthesis cAMP-, cIMP-
and cUMP-production amounted to 8%, 26% and 3.5%,
respectively. To this end, we have not detected cCMP or
cTMP production. Cytosine 5' triphosphate (CTP) and
thymidine 5'-triphosphate (TTP) will be further examined
as potential sGC substrates following method optimiza-
tion regarding incubation time and protein concentra-
tion.
Conclusion
Our results show that sGC has broader substrate specifi-
city than previously assumed. We could demonstrate that
not only bacterial toxins [see poster: M Göttle et al.] but
also a mammalian enzyme of high physiological impor-
tance catalyses the biosynthesis of rare cNMPs such as
cUMP and cIMP.
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